Oncoinvent ASA (OSL:ONCIN)

Market Cap	180.83M
Revenue (ttm)	8.10M
Net Income (ttm)	-140.20M
Shares Out	97.74M
EPS (ttm)	-1.52
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	42,231
Average Volume	155,670
Open	1.800
Previous Close	1.702
Day's Range	1.710 - 1.990
52-Week Range	1.150 - 4.000
Beta	n/a
RSI	48.44
Earnings Date	Aug 27, 2025

About Oncoinvent ASA

Oncoinvent ASA, a clinical stage company, develops radiopharmaceutical therapies against cancer. Its lead product candidate is Radspherin, alpha-radiation therapy candidate designed for the direct targeting of cancers that have spread to body cavities, like the peritoneum in two phase 1/2a trials and one randomized phase 2 trial. The company was incorporated in 2010 and is based in Oslo, Norway.

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2010
• Employees: 34
• Stock Exchange: Oslo Børs
• Ticker Symbol: ONCIN

Financial Performance

In 2024, Oncoinvent ASA's revenue was 8.10 million, an increase of 39.95% compared to the previous year's 5.79 million. Losses were -140.20 million, -2.38% less than in 2023.